These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas. Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946 [TBL] [Abstract][Full Text] [Related]
3. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts. Schweizer L; Capper D; Hölsken A; Fahlbusch R; Flitsch J; Buchfelder M; Herold-Mende C; von Deimling A; Buslei R Neuropathol Appl Neurobiol; 2015 Oct; 41(6):733-42. PubMed ID: 25442675 [TBL] [Abstract][Full Text] [Related]
4. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma]. Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087 [No Abstract] [Full Text] [Related]
6. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases. Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561 [TBL] [Abstract][Full Text] [Related]
7. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma? Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631 [TBL] [Abstract][Full Text] [Related]
9. Endoscopic endonasal versus open transcranial resection of craniopharyngiomas: a case-matched single-institution analysis. Moussazadeh N; Prabhu V; Bander ED; Cusic RC; Tsiouris AJ; Anand VK; Schwartz TH Neurosurg Focus; 2016 Dec; 41(6):E7. PubMed ID: 27903116 [TBL] [Abstract][Full Text] [Related]
10. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells. Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055 [TBL] [Abstract][Full Text] [Related]
11. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature. Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716 [TBL] [Abstract][Full Text] [Related]
12. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321 [TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106 [No Abstract] [Full Text] [Related]
14. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation. Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464 [TBL] [Abstract][Full Text] [Related]
15. Preservation of Hypothalamic Function with Endoscopic Endonasal Resection of Hypothalamus-Invaded Craniopharyngiomas. Yang L; Xie SH; Fang C; Zeng EM; Tang B; Hong T World Neurosurg; 2019 Dec; 132():e841-e851. PubMed ID: 31398519 [TBL] [Abstract][Full Text] [Related]
16. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026 [TBL] [Abstract][Full Text] [Related]
17. Outcomes following endoscopic, expanded endonasal resection of suprasellar craniopharyngiomas: a case series. Gardner PA; Kassam AB; Snyderman CH; Carrau RL; Mintz AH; Grahovac S; Stefko S J Neurosurg; 2008 Jul; 109(1):6-16. PubMed ID: 18590427 [TBL] [Abstract][Full Text] [Related]
18. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes]. Fujio S; Hanaya R No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344 [TBL] [Abstract][Full Text] [Related]
19. Systematic review of transcranial and endoscopic endonasal approaches for craniopharyngiomas in children: is there an evolution? d'Avella E; Vitulli F; Berardinelli J; Cinalli G; Solari D; Cappabianca P; Cavallo LM J Neurosurg Pediatr; 2024 Jan; 33(1):73-84. PubMed ID: 37948683 [TBL] [Abstract][Full Text] [Related]
20. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]